Pages that link to "Q43899090"
Jump to navigation
Jump to search
The following pages link to Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. (Q43899090):
Displaying 50 items.
- A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding (Q21132301) (← links)
- Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas (Q26751724) (← links)
- Neoadjuvant radiotherapeutic strategies in pancreatic cancer (Q26766686) (← links)
- The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates (Q26865015) (← links)
- Neoadjuvant therapy for pancreas cancer: past lessons and future therapies (Q27004292) (← links)
- Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker (Q30513800) (← links)
- Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). (Q30534663) (← links)
- Serum CA19-9 in patients with solid pancreatic mass (Q33596555) (← links)
- A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer (Q33728198) (← links)
- Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study (Q33780907) (← links)
- Intensity of follow-up after pancreatic cancer resection (Q33791048) (← links)
- The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells (Q33826323) (← links)
- Risk factors for pancreatic adenocarcinoma and prospects for screening. (Q33916380) (← links)
- Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation (Q33928253) (← links)
- Screening for pancreatic cancer: why, how, and who? (Q33959412) (← links)
- Borderline resectable pancreatic cancer: definitions and management (Q34067852) (← links)
- Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers (Q34119094) (← links)
- Pancreatic adenocarcinoma (Q34140498) (← links)
- Serum HSP70: a novel biomarker for early detection of pancreatic cancer. (Q34322212) (← links)
- Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expr (Q34408283) (← links)
- Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704 (Q34600819) (← links)
- The prognostic and predictive value of serum CA19.9 in pancreatic cancer (Q34635104) (← links)
- Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials (Q34665177) (← links)
- Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection (Q34995279) (← links)
- Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution (Q35046670) (← links)
- Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma (Q35627199) (← links)
- Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies (Q35678051) (← links)
- A Novel Multivariate Index for Pancreatic Cancer Detection Based On the Plasma Free Amino Acid Profile (Q35680475) (← links)
- CA 19-9 as a serum marker in urothelial carcinoma (Q35970605) (← links)
- Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer (Q36064780) (← links)
- Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer (Q36079626) (← links)
- Advances in biomarker research for pancreatic cancer (Q36126609) (← links)
- The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma (Q36191929) (← links)
- Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma. (Q36213547) (← links)
- The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real? (Q36272668) (← links)
- Pancreatic Cancer: a Challenge to Cure (Q36400081) (← links)
- Strategies for discovering novel pancreatic cancer biomarkers (Q36579311) (← links)
- CA 19-9 and pancreatic cancer (Q36786361) (← links)
- Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma (Q36793155) (← links)
- Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation (Q37011364) (← links)
- Molecular markers of pancreatic cancer: development and clinical relevance (Q37081461) (← links)
- ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma (Q37165264) (← links)
- Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer (Q37339612) (← links)
- CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy (Q37398718) (← links)
- CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone (Q37400577) (← links)
- The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma (Q37611396) (← links)
- Increased expression of αTubulin is associated with poor prognosis in patients with pancreatic cancer after surgical resection (Q37645079) (← links)
- Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort (Q37682867) (← links)
- Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. (Q37701172) (← links)
- Composition and production of pancreatic tumor related antigens (Q37785581) (← links)